We have one of the World s Most Advanced Functional HIV Cures under development
|
|
- Maurice Bruce
- 6 years ago
- Views:
Transcription
1 Source : labiotech.eu, 04/07/2016 We have one of the World s Most Advanced Functional HIV Cures under development Abivax has recently announced that it s likely that its most advanced program in hepatitis B will fail its Phase III trials. That s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company s CEO Hartmut Ehrlich and its CMO Jean-Marc Steens Abivax is one of the high-profile Biotechs in Paris. With a pipeline with candidates for hepatitis B and HIV, it raised 57M during its IPO on the Euronext Paris the biggest ever in French Biotech. But its stock price is now suffering from the most recent news. Abivax has announced that its Phase III for hepatitis B is not having the best results, and it s very unlikely that the primary endpoint will be met essentially a Phase III failure. ABX-203 is still Abivax s most advanced candidate and was leading the race for a hepatitis B virus treatment. It was the result of a collaboration with Cuban Life Sciences. In fact, the same product was already approved in Cuba.
2 The mechanism of action of ABX-203, a candidate for hepatitis B. So what happened in this trial? The results surprised our colleagues in Cuba, and they also surprised the key opinion leaders that were involved in this study, says Hartmut Ehrlich, CEO of Abivax. He went on to explain the key difference between the studies. In Cuba, the enrolled patients hadn t been treated with antivirals before, whereas in this trial the patients had also been treated with nucleoside analogues (another therapy for hepatitis B). And how this impacted the results was not predictable. We will be able to do the complete analysis to understand what has been going on there, but it is certainly premature to draw conclusions on how we are moving forward. If there s a future for ABX-203, Ehrlich estimates that the setback will of at least a couple of years. Abivax s stock price fell by over 50% upon this announcement (as of 30/06), which brings its market cap below the amount raised in the IPO. For the moment, the news is really bad if someone is selling, admits Ehrlich.
3 Abivax s shareholder structure. However, valuation is not an imminent problem for Abivax. At the end of last year, the company s cash position was 39M. The cash is certainly sufficient to develop programs until the end of It s up to us to bring the stock price back to where we would like to see it. And its HIV program would be key to raising the company s value. Abivax is developing ABX-464, which is described as a functional cure for HIV. I was curious as to what that meant exactly Jean-Marc Steens (CMO of Abivax) jumped in to explain: ABX-464 is different of traditional antiretrovirals, which keep circulatory HIV virus down. Our drug targets the reservoirs where the virus is hiding. The therapy blocks the replication of the virus in the reservoir. So this would be a functional cure as there wouldn t be a source of new copies of the virus.
4 ABX464 is an antiviral candidate thought to inhibit the RNA replication of the HIV Virus Of course, targeting HIV reservoirs is an approach that already caught the eye of big Pharma and is getting some impressive preclinical results. Everybody is looking at it, but we are very advanced now starting our second Phase IIa trial. We believe we are in a really good position here, Ehrlich explained. I also really got the feeling that Abivax is taking it one step at a time with this program. It first proved an antiviral response in treatment-naive in a first Phase IIa. Now, a second Phase IIa will compare the time for viral rebound in patients that already have their infection under control with current therapies. Abivax s chief medical officer (CMO), Jean-Marc Steens. However, there s more about Abivax than just HIV ABX-464 is only the frontrunner of numerous potential products. The drug is the result of the company s antiviral platform, which has also produced candidates for viruses like dengue and chikungunya. There s also a second platform in development, which originated a candidate for Ebola.
5 Platform for generation of antiviral compounds. So it seems a lot of the value might be on these antiviral programs and the platforms, and not so much on the now-failing Hepatitis candidate. This is the way we look at it, he confirmed. In this sense, Abivax s situation is closer to Celyad (which failed in heart failure but still has CAR-T) than Circassia (for which a Phase III failure halted a large chunk of the pipeline). Perhaps this isn t such a bad turn in this case. And on a positive note, he ended with We are not afraid of moving forward.
Top-line results of the phase IIa study with ABX464 in ulcerative colitis
TARGETING THE IMMUNE SYSTEM TO ELIMINATE VIRAL AND INFLAMMATORY DISEASE Top-line results of the phase IIa study with ABX464 in ulcerative colitis October 2018 Forward looking statements This presentation
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationMedivir at. Avanza s Företagsdag 10 december Lars Adlersson, CEO Börje Darpö, VP Development
Medivir at Avanza s Företagsdag 10 december 2008 Lars Adlersson, CEO Börje Darpö, VP Development Medivir contact rein.piir@medivir.se www.medivir.com Medivir Key achievements 2008 Strong phase IIa data
More informationBIOTRON TO PRESENT AT AUSTRALIA BIOTECH INVEST 2013
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 October 2013 The Manager Companies ASX Limited 20
More informationBIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018
BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au Forward Looking Statements This presenta8on may contain
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationAbivax S.A. (ABVX.PA)
Initiating Coverage March 1, 2016 Abivax S.A. (ABVX.PA) Initiation Report LifeSci Investment Abstract Abivax SA (Euronext Paris: ABVX.PA) is developing novel therapies to treat serious infectious diseases.
More informationEarly Antiretroviral Therapy
Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative
More informationwe ve got fine tuning possibilities, and that s certainly possible with modifying the enzymes that synthesize or degrade the endogenous cannabinoids
The CCIC Podcast February 24, 2015 This month: Prof. Steve Alexander Interview by Dr. Mark A. Ware www.ccic.net/podcast Introduction Hello and welcome to the CCIC Podcast. The CCIC Podcast is a series
More informationThe Ultimate Herpes Protocol Review
The Ultimate Herpes Protocol Review After reading so many reviews, you must be wondering if the Ultimate Herpes Protocol is scam or legit? Before answering this question, I would like do a comprehensive
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More informationIntegrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson
Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present
More informationRENOUNCEABLE RIGHTS ISSUE
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 25 May 2017 The Manager Companies ASX Limited 20 Bridge
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationNon-profit education, research and support network offers money in exchange for missing science
Alive & Well $50,000 Fact Finder Award Find One Study, Save Countless Lives Non-profit education, research and support network offers money in exchange for missing science http://www.aliveandwell.org Tel
More informationPRESENTATION TO INVESTORS. I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, to investors today.
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 11 November 2010 The Manager Companies ASX Limited
More informationPREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day
PREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day Dr. Jim Gimlett, Program Manager DARPA Biological Technologies Office (BTO) January 30, 2018 Arlington, VA PREEMPT Agenda Proposers Day Objectives
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
More informationThe Cinderella Hypothesis
The Hypothesis The Cinderella Hypothesis The Unique Opportunity that s Unfolding for Trigger Point Specialists For people who think they know all about trigger points There s something 90% of people have
More informationDr. Coakley, so virtual colonoscopy, what is it? Is it a CT exam exactly?
Virtual Colonoscopy Webcast January 26, 2009 Fergus Coakley, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationWhat Does HIV Do to You?
What Does HIV Do to You? HIV and the immune system Your immune system is supposed to protect you from viruses and other infections. Why, then, doesn t it protect you from HIV? The answer is complicated,
More informationInformation Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date
Positive News Information Magazine for people with Hepatitis C and HIV Hepatitis C - Treatment in people with haemophilia, the results to date From July 2012 to October 2013, a total of fifteen persons
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen and Company 7 th Annual Global Healthcare Conference November 7, 2006 Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Safe Harbor This
More informationLecture 2 Evolution in action: the HIV virus
Lecture 2 Evolution in action: the HIV virus Peter and Rosemary Grant Barry Sinervo The HIV/AIDS pandemic Life expectancy in Botswana What is HIV? What is HIV? HIV is a retrovirus (i.e., RNA-based) with
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationAn Update on BioMarin Clinical Research and Studies in the PKU Community
An Update on BioMarin Clinical Research and Studies in the PKU Community Barbara Burton, MD, Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Director of PKU Clinic, Children
More informationSpeech by The Rt Hon David Cameron
Defeating dementia: progress and challenges on the road to 2025 London, 5 December 2018 Speech by The Rt Hon David Cameron Former UK Prime Minister 2010-16 Why Dementia Few things are as sad as seeing
More informationIntroduction. Preliminary POV. Additional Needfinding Results. CS Behavioral Change Studio ASSIGNMENT 2 POVS and Experience Prototypes
CS 147 - Behavioral Change Studio ASSIGNMENT 2 POVS and Experience Prototypes Introduction Meet The BetterMeet Team We are a team of Stanford students in the behavioral change studio. Problem Domain Our
More informationHandelsbanken November Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR
Handelsbanken November 18 2009 Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR Pipeline Project Indication(s) Partners/- date of Explorati Optimiz agreement Terms Medivir's markets ve phase
More informationBioDiem to present at Hong Kong biotech investment forum
ASX Announcement BIODIEM LTD ABN 20 096 845 993 Suite 3, Level 11, 470 Collins Street, Melbourne, Victoria, 3000 Australia Phone: +613 9613 4100 Web: www.biodiem.com BioDiem to present at Hong Kong biotech
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationNew Treatments to Reduce Liver Damage From Hepatitis B
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/new-treatments-to-reduce-liver-damage-from-hepatitisb/3994/
More informationLetter of Amendment # 3 to:
Letter of Amendment # 3 to: HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States Version 1.0, dated 8 October 2015 DAIDS
More informationTwo Basic Scientists Walk into a Translational Space
Lasker Awards Conversations Two Basic Scientists Walk into a Translational Space When John Schiller first joined Douglas Lowy s lab at the National Cancer Institute of the NIH, he could have not predicted
More informationLESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV
LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent
More informationToolkit Instructions. Read and complete the 5 assignments in this toolkit.
Keep it Safe Toolkit Toolkit Instructions Read and complete the 5 assignments in this toolkit. N. G. Bartholomew, D. F. Dansereau, K. Knight, and D. D. Simpson TCU Institute of Behavioral Research Welcome
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationWntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
More informationFlex case study. Pádraig MacGinty Owner, North West Hearing Clinic Donegal, Ireland
Flex case study Pádraig MacGinty Owner, North West Hearing Clinic Donegal, Ireland Pádraig MacGinty has been in business for 15 years, owning two clinics in North West Ireland. His experience with Flex:trial
More informationR&D Webinar: Product Pipeline Update
R&D Webinar: Product Pipeline Update Dr. Mark Murray, President & CEO Dr. Mark Kowalski, Chief Medical Officer Dr. Ian MacLachlan, Chief Scientific Officer Ian Mortimer, Executive Vice President Bruce
More informationCANCER HAS BEEN AROUND
For decades, drug companies have been spending billions of dollars and countless hours on researching and developing treatments and cures for cancer. The reason is easy to understand. Cancer is the second-leading
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationPhylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies
Phylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies Disclaimer The purpose of the presentation is to provide an
More informationJeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine.
Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine. 1 2 On April 30 the VU and VUMC transition was completed and we
More informationSecrets to the Body of Your Life in 2017
Secrets to the Body of Your Life in 2017 YOU CAN HAVE RESULTS OR EXCUSES NOT BOTH. INTRO TO THIS LESSON Welcome to Lesson #3 of your BarStarzz Calisthenics Workshop! For any new comers, make sure you watch
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationor seen with seasonal influenza. So we will continue to follow this and see how the picture of clinical symptoms evolves.
Transcript of Virtual Press conference with Dr Keiji Fukuda, Assistant Director-General ad. Interim for Health Security and Environment World Health Organization 29 April 2009 Dr Fukuda: Good afternoon
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationTransgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy
Transgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy Parc d Innovation, Illkirch, France, March 22, 2010 Transgene (Euronext Paris: FR0005175080) details its
More informationPractices for Demonstrating Empathy in the Workplace
Practices for Demonstrating Empathy in the Workplace These practices have been developed to help leaders at all levels to develop and demonstrate empathy. These practices, when employed in combination,
More informationUnit 4 Student Guided Notes
Structure of Viruses Discovery of the Virus Unit 4 Student Guided Notes Many human epidemics were well documented and observed in history, but. The following 3 discoveries shaped our knowledge of viruses
More informationVERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION
VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION Study Title: Cytokine Production and Lymphoproliferation With and Without Co-inhibitory Signaling Blockade: An Assessment of Functional
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationA handbook for people who have injected drugs
A handbook for people who have injected drugs Introduction This handbook has been written for current and ex-drug injectors. It gives information and advice about the hep C virus, and the tests you can
More informationSCIENTIFIC PROGRAM ORAL PRESENTATIONS. Friday October, 26 th OPENING SESSION
SCIENTIFIC PROGRAM Friday October, 26 th OPENING SESSION 16:40-17:00 Opening lectures on Infectious Diseases 17:00-19:00 Opening lectures on Infectious Diseases Dr. Gerardo Guillén (Director of Biomedical
More informationPRESENTATION AT BIOTECH INVEST 2016
4 May 2016 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website:
More informationLaboratories That Offer the Ultra-senstive PCR Test to Individuals
National AIDS Treatment Advocacy Project Laboratories That Offer the Ultra-senstive PCR Test to Individuals On July 14 and 15, 1997, the FDA held a public hearing to discuss using viral load as a primary
More informationImmuno-Oncology: Perspectives on Current Therapies & Future Developments
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/immuno-oncology-perspectives-currenttherapies-future-developments/9502/
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationSection 4 - Dealing with Anxious Thinking
Section 4 - Dealing with Anxious Thinking How do we challenge our unhelpful thoughts? Anxiety may decrease if we closely examine how realistic and true our unhelpful/negative thoughts are. We may find
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More information3. Which word is an antonym
Name: Date: 1 Read the text and then answer the questions. Stephanie s best friend, Lindsey, was having a birthday in a few weeks. The problem was that Stephanie had no idea what to get her. She didn t
More informationLiving My Best Life. Today, after more than 30 years of struggling just to survive, Lynn is in a very different space.
Living My Best Life Lynn Allen-Johnson s world turned upside down when she was 16. That s when her father and best friend died of Hodgkin s disease leaving behind her mom and six kids. Lynn s family was
More informationHepatitis C, Cured By Johnny Delirious
Hepatitis C, Cured By Johnny Delirious The Future of Hepatitis C Treatment - Healthline - Several hepatitis C treatments currently being researched. Learn about these potentially game-changing treatments,
More informationFor any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
More informationPractical Brain-Focused Strategies for Working with Depression
Practical Brain-Focused Strategies for Working with Depression Video 4 - Transcript - pg. 1 Practical Brain-Focused Strategies for Working with Depression How to Ignite the Depression-Battling Part of
More informationAdditional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T
September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T
More informationTRANSCRIPT: WHO S IN CONTROL? The carriage is empty, except for three people sitting at a table. All are smartly dressed.
TRANSCRIPT: WHO S IN CONTROL? An express train thunders past. INSIDE The carriage is empty, except for three people sitting at a table. All are smartly dressed. So what will you be saying at the conference?
More informationScience World Journal of Cancer Science and Therapy
Open Access Journal Volume: 1.1 Science World Journal of Cancer Science and Therapy Establishment of Investment after Manufacturing Natural Remedy for Blood Circulation Virus Killing Immune Oncology Cured
More informationLiving Immunotherapies. Corporate Presentation OCTOBER 2018
Living Immunotherapies Corporate Presentation OCTOBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation
More informationTotal English Placement Test
Name Class Total English Placement Test PART A Choose the best answer. Mark it with an X. If you do not know the answer, leave it blank. 1 name is Robert. a) Me b) I c) My 2 They from Spain. a) is b) are
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationIdenix Pharmaceuticals: Building a Leading Antiviral Franchise. Jean-Pierre Sommadossi Chairman and Chief Executive Officer Spring 2006
Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Jean-Pierre Sommadossi Chairman and Chief Executive Officer Spring 2006 Safe Harbor This presentation includes forward-looking statements
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationConsultation on WHO ART Guidelines
Consultation on WHO ART Guidelines Defining Standards of Treatment and Care ICAAP9, Bali, Indonesia Global Network of People Living with HIV Asia Pacific Network of People Living with HIV August 2009 Introduction
More informationPneumococcal Vaccines: Questions and Answers
Pneumococcal Vaccines: Questions and s Question 1 What is pneumococcal disease? What is pneumococcal disease? So pneumococcal disease is a group of diseases that are caused by a bacteria. Most of us are
More informationDraft 0-25 special educational needs (SEN) Code of Practice: young disabled people s views
Draft 0-25 special educational needs (SEN) Code of Practice: young disabled people s views Young people s consultation When I used to on have the my reviews at school they never used to tell me what was
More informationFind out more at: OUR MISSION
Find out more at: www.gilead.com/yir2017 SCIENTIFIC INNOVATION & ADDRESSING UNMET NEEDS Gilead uses its scientific expertise to help transform and simplify care for people with life-threatening illnesses
More informationMortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013
John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationWhat Women Need to Know: The HIV Treatment Guidelines for Pregnant Women
: The HIV Treatment Guidelines for Pregnant Women : The HIV Treatment Guidelines for Pregnant Women What Women Need to Know: Prepared by Elaine Gross, RN, MS, CNS-C National Pediatric & Family HIV Resource
More informationDr. Susan Steen: I have a special interest in dementia and Alzheimer s in related disorders.
Saving Memories With a Shake: The Alzheimer's Drink Susan Steen, MD Susan Steen, MD, a neurologist at South Tampa Memory Center/President, Axiom Clinical Research, talks about a new medical food for Alzheimer's
More informationother chronic conditions, which can be illnesses such as diabetes or lung disease or some form of immunodeficiency and so on. This is in-keeping with
Transcript of virtual press conference with Gregory Hartl, WHO Spokesperson for Epidemic and Pandemic Diseases, and Dr Keiji Fukuda, Assistant Director-General ad Interim for Health Security and Environment,
More informationMortality Slide Series. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention
Mortality Slide Series National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention HIV Mortality Slides An analysis of trends in rates and distributions of deaths
More informationHepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/
More informationDealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep
Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:
More informationRXi Pharmaceuticals. Building leadership in RNAi and Immunotherapy. Research Note.
Research Note RXi Pharmaceuticals Building leadership in RNAi and Immunotherapy Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More informationInvestigating Plinabulin as Immune-Modifying Therapy for Non-Small Cell Lung Cancer (NSCLC)
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/project-oncology/beyondspring-birnholzmita/9543/
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationEmerging Viruses. Part IIb Follow Up from Part I Vaccines and Inhibitors
Emerging Viruses Part IIb Follow Up from Part I Vaccines and Inhibitors Cellular Responses to Viral Invasion: Restriction Factors Cells fight viral infection using a series of restriction factors Restriction
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationVivaGel BV. Product Information and Independent Market Research 30 APRIL 2018 STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY
VivaGel BV Product Information and Independent Market Research 30 APRIL 2018 STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY Important notice and disclaimer This document contains certain forward-looking
More informationAdvances in Viral Immunity Stemming from the 1918 Flu Pandemic
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/advances-in-viral-immunity-stemming-from-the-
More information